Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8NBJ5
UPID:
GT251_HUMAN
Alternative names:
Collagen beta(1-O)galactosyltransferase 1; Glycosyltransferase 25 family member 1; Hydroxylysine galactosyltransferase 1
Alternative UPACC:
Q8NBJ5; Q8NC64
Background:
Procollagen galactosyltransferase 1, also known as Collagen beta(1-O)galactosyltransferase 1, plays a crucial role in collagen biosynthesis. It is responsible for transferring beta-galactose to hydroxylysine residues of type I collagen, facilitating the formation of the collagen triple helix. This enzyme is also involved in the biosynthesis of collagen type IV, highlighting its importance in maintaining the structural integrity of various tissues.
Therapeutic significance:
The enzyme's association with Brain small vessel disease 3, a condition characterized by cerebrovascular defects leading to developmental delays and neurological deterioration, underscores its therapeutic significance. Understanding the role of Procollagen galactosyltransferase 1 could open doors to potential therapeutic strategies for treating or managing this debilitating disease.